New insider activity at ADARx Pharmaceuticals ( (ADRX) ) has taken place on September 30, 2026.

ADARx Pharmaceuticals has drawn significant insider interest, with three company directors making sizable open-market stock purchases. Investment firm director Orbimed Advisors LLC acquired 950,000 shares of ADARx Pharmaceuticals in a transaction worth $16,150,000. Director Carl Gordon matched this move, also buying 950,000 shares for $16,150,000. Adding to the wave of insider buying, Director Erez Chimovits purchased 61,516 shares of the company’s stock, in a deal valued at $1,045,772. These transactions highlight a strong show of confidence in ADARx Pharmaceuticals from its leadership and major stakeholders.